cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Transcranial Direct Current Stimulation in Acute Ischemic Stroke

Non-invasive brain stimulation (tDCS) such as transcranial direct current stimulation (TDCS) has been reported to be effective in improving motor performance and safe in participants with cerebral infarction. However, few studies have been done in participants with acute cerebral infarction. In this study, the investigators want to see the effect of tDCS in acute cerebral infarction. the investigators perform tDCS in participants with acute ischemic stroke within 48 hours after stroke onset and the investigators measure motor weakness and function at early phase as well as at 3 months.

Cerebral infarction is a major cause of death, a disease that is socially and nationally burdensome, leaving disabilities and dementia behind.

In participants with cerebral infarction, non-invasive brain stimulation (tDCS) such as transcranial direct current stimulation (TDCS) has been reported to be effective in improving motor performance and safe. However, few studies have been done in participants with acute cerebral infarction, and previous studies in participants with acute cerebral infarction have not verified the effect in mild cerebral infarction, and previous studies in acute cerebral infarction mainly stimulate lesions to anode. So in this study, the investigators want to see the effect of stimulating tDCS to both hemispheres in acute cerebral infarction against this backdrop.

Study Objective: To see if tDCS is effective in improving motor paralysis in participants with acute cerebral infarction.

Expected effectiveness: stability of tDCS has already been demonstrated in many studies. Since tDCS itself is a non-invasive treatment, if the efficacy of the tDCS prove to be effective in patients with acute cerebral infarction, it can be widely implemented without significant risk to many patients.

Intervention : In this randomized controlled trial, the investigators perform tDCS in patients with acute ischemic stroke within 48 hours after stroke onset with sham control.

Outcome : the investigators measure motor weakness and function at early phase as well as at 3 months.

Eligibility Criteria:
Inclusion Criteria:

* ischemic stroke patients within 2 days stroke onset
* 18-85 of age
* corticospinal tract involvement stroke (primary motor cortex, corona radiata, internal capsule, midbrain crus cerebri, basis pontis, anterior medulla)

Exclusion Criteria:

* pre-stroke disability (defined as modified Rankin Scale (mRS) \>=2)
* Intravenous r-tPA thrombolysis or EVT (endovascular thrombectomy)
* history of epilepsy
* advanced systemic disease or coexisting neurological/psychiatric disease
* severe contact dermatitis or skin lesions interfering with the applying the electrode of tDCS
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.


Eligibility Criteria:
* Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).
* Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.
* Patients may not have any history of brain and/or leptomeningeal metastases.
* Patients may not have Grade 2 or worse neuropathy at the time of study entry.
* Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease

The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple sclerosis. There are multiple studies to suggest that persons with multiple sclerosis benefit from this medication and have major improvements in gait after taking this medication. However, this medication was never studied in Parkinson's disease. This study aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).

Subjects with Parkinson's disease will be randomly assigned to two groups. One group will receive Ampyra first for 4 weeks, followed by 2 weeks break and than 4 weeks placebo while the second group will first receive placebo and then Ampyra.

Eligibility Criteria:
Inclusion Criteria:

* Idiopathic PD with stage Hoehn and Yahr Stage\>2-3 and with gait freezing or postural instability.
* On stable dosage dopamine agonist/levodopa, and expected to remain on the same dosage of treatment for the duration of study
* Age less than 80, onset of disease at age more than 45.
* Able to give consent

Exclusion Criteria:

* Past medical history of seizures,
* History of renal insufficiency,
* History of cardiac arrhythmia,
* Severe arthritis,
* Women of childbearing potential,
* Cognitive impairment
* Age more than 80.
* PD patients stage 4 H\&Y
* PD patient with recent introduction of dopamine agonist or IMAO B
* PD patients participating in other studies
Improvement After Physiotherapy for Low Back Pain: The Good Responders

This is an observational study that aims to characterize individual response of patients getting physical therapy for chronic non-specific low back pain.

Participants will be classified based on a questionnaire and motor tests to investigate whether individual improvement after physical therapy may be predicted. These observations may help to decide which should be the preferred treatment offered.


Eligibility Criteria:
Inclusion Criteria:

* low back pain
* receiving primary care physiotherapy

Exclusion Criteria:

-

-
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

In this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).


Eligibility Criteria:
Inclusion Criteria:

* Patients with confirmed diagnosis of chronic phase CML within last 3 months
* Patients with cytogenetically confirmed Ph positive CML in early chronic phase

Exclusion Criteria:

* Patients with Philadelphia chromosome negative but BCR-ABL positive CML
* Patients who used imatinib for 8 days or longer before study entry
* Patients who had been treated with other targeted anti-cancer therapy, except for Hydrea or Agrylin, which inhibits the growth of leukemic cells
* Patients with impaired cardiac function
* Cytologically confirmed CNS involvement
* Severe or uncontrolled chronic medical condition
* Other significant congenital or acquired bleeding disorders that are not related to underlying leukemia
* Patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery
Embryo DNA Repair Capacity Project

The mail aim of the present study is to use molecular methods to analyze the ability of human preimplantation embryos to repair their DNA

The main aim of the present study is to investigate the DNA repair pathways of preimplantation embryos, examining the events that take place following induction of a DSB at a unique targeted site. The investigators aim to address questions concerning the functionality of the DNA repair mechanism(s) in developing embryos, before and after genome activation.

Eligibility Criteria:
Inclusion Criteria:

* gamete donors: be at least 21 years of age, in good health and eligible to donate their games through the standard gamete donation programs
* IVF couples: any couples proceeding with a routine IVF cycle

Exclusion Criteria:

* less than 21 years of age
* inability to provide informed consent
Clinical Bioequivalence Study on Two Metoprolol Tablet 100mg Formulations

The purpose of the study is to compare the bioavailability of a generic product of metoprolol with that of a reference product when administered to healthy volunteers under fasting conditions. The test product is BF-Metoprolol Tablets 100mg manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited and the reference product is Betaloc Tablet 100mg. The plasma kinetic data of metoprolol obtained from two formulations will be used to access the interchangeability of the products.

The study design is a single-dose, two-treatment, two-period, two-sequence cross over with a washout period of one to two weeks. Subject will be randomly assigned to two groups corresponding to two dosing sequences. Each subject will undergo two study (treatment) sessions, during which a single oral dose of 100mg metoprolol from either test or reference formulations will be administered. The estimated duration of subject's participation will be about 29-36 days (i.e. 3 weeks for screening and medication restraint, 1 day each for study (treatment) sessions I and II, 1 - 2 weeks as washout period. Venous blood samples will be collected at pre-dose (0h), and up to 24h post dose. The plasma concentrations of metoprolol will be determined by a validated assay. The non-compartmental method will be used to analyze the plasma concentration-time data and calculate the main pharmacokinetic parameters such as Cmax, Tmax, AUC0-last, AUC0-inf, and T1/2. ANOVA will be calculated on logarithmically transformed Cmax, AUC0-last and AUC0-inf. The two one sided tests will be used to calculate the 90% confidence intervals for the mean difference in AUC0-last, AUC0-inf and Cmax and to assess the bioequivalence of the two products

Eligibility Criteria:
Inclusion Criteria:

* Male and non-pregnant female, 18 to 55 years of age
* Body Mass Index between 18 to 30 kg/m2
* Accessible vein for blood sampling
* High probability for compliance and completion of the study
* Female subjects must agree to practice abstinence or take effective contraceptive methods to prevent pregnancy from the start of the screening and until two weeks of last dose administration

Exclusion Criteria:

* Clinically significant hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to the study
* Clinically significant abnormality in physical examination, vital sign, laboratory test results, ECG evaluation, urine test, blood chemistry or haematological test
* Regular consumption of tobacco used in any forms
* Regular consumer of alcohol (more than one drink per day)
* Blood donation within 4 weeks prior to the start of the study
* Use of metoprolol within 4 weeks before the study
* Use of antihypertensive medications or other beta blockers within 4 weeks before the study
* Volunteer in any other clinical drug study within 2 months prior to this study
* Hypersensitivity to metoprolol or other drugs in its class
* History of drug abuse in any form
* Female subjects who are breastfeeding or pregnant
Identifying Residential Hazards Using Home Test Kits

The purpose of this project is to help families and communities identify and reduce health risks from lead, pesticides and, ultimately, other environmental hazards. We have partnered with the Better Housing League and Baby's Milk Fund in Cincinnati and nationally with the Alliance to End Childhood Lead Poisoning and the National Center for Lead Safe Housing. The first specific aim of this project is to evaluate a sampling kit for families to assess levels of lead and pesticides in their home environment. This aim will strengthen right-to-know laws by providing families with tools to assess environmental contamination in their own homes. The second aim is to increase community awareness of the role of environmental agents in developmental disorders, hearing loss and school problems.

A cross-sectional random, stratified study design will be used for this project. All children who are younger than 5 years of age and have a venipuncture blood sample taken at the babies Milk Fund Clinic will be eligible for this study. After checking the lists for errors and duplications, we will randomly permute the sampling frame, stratifying on children's blood lead concentration. Stratification will be used to enroll about 33% of the sample with blood lead concentrations below 5 mg/dl, 33% between 5 to 10 mg/dl, and 33% of 10 mg/dl or higher. Stratifying the sample will improve our chances of testing the predictive validity of home sampling kits to identify children who have blood lead concentration \> 10 mg/dl collected by families. In addition this study will:

1. Develop a pesticide wipe sampling kit to accompany our lead-sampling kit.
2. Evaluate the predictive validity of home sampling kits for lead-contaminated floor dust to identify children who have blood lead levels of 10 mg/dl or higher by community participants compared with repeat samples taken by trained, community workers.
3. Evaluate the reliability of home sampling kits for pesticides in dust collected by community participants compared with trained, community workers.
4. Disseminate data on the reliability of home sampling tests and provide tools for families to collect environmental samples for large, population-based studies.
5. Develop a Healthy Homes Resource Center at the Better Housing League to disseminate information to the community about residential hazards.

Eligibility Criteria:
Inclusion Criteria:

Venous blood lead In residence 3 months Child less than 5 years of age Sampler greater than 18 years of age

Exclusion Criteria:

Cannot read or understand English Physically unable to conduct field sampling Outside of theGreater Cincinnati area
A Trial to Compare the Laser Treatment (SLT vs. ALT) in Glaucoma Patients

Lasers are important therapy in glaucoma. They are a pivotal point in treatment between medical and surgical care. Over the last 10 years a new laser has emerged as the usual laser treatment: Selective laser trabeculoplasty (SLT). SLT works as well as the older laser used: argon laser trabeculoplasty (ALT). However SLT has many theoretical benefits over ALT including causing less damage to the tissue it affects. One of the potential patient centered benefits of this laser is that it may be repeatable. It is even possible that the old laser ALT may be useable after an SLT treatment. This study aims to uncover whether repeat laser is possible after SLT and if so which laser is more effective (ALT vs SLT). The potential of repeating laser therapies may delay surgical treatment and its complications. Also understanding which laser to use will help eye doctors know how to treat their patients at this point of the disease.


Eligibility Criteria:
Inclusion Criteria:

* Over age of 18 yo.
* OAG including pigmentary dispersion syndrome and pseudoexfoliation
* OAG has been treated with 360 degrees of SLT
* two sighted eyes,
* willing to participate after being informed of and reading the patient information material.

Exclusion Criteria:

* Narrow angle glaucoma
* Previous glaucoma surgery
* Eye surgery expected in the next 12 months
* Severe corneal disease
* On or anticipated steroid in 6 months
* Pregnant or breast feeding
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

To investigate the potential of preoperative initiation (3 days) and perioperative continuation (until day 2 after surgery) of empagliflozin(sodium glucose co transporter 2 inhibitor(SGLT-2i)) 10 mg daily to reduce the acute kidney injury marker neutrophil gelatinase-associated lipocalin (NGAL) measured in serum and urine on day 2 postoperatively in patients undergoing cardiopulmonary bypass surgery by comparing a study medication group to a control group in an open-label set-up.

Adult patients scheduled for elective cardiopulmonary bypass assisted cardiothoracic surgery will be informed about the study and after receiving informed consent will be divided between two groups in an openlabel fashion:

Intevention group: Takes study medication(10mg Empagliflozin once a day in the morning) 3 days prior to surgery, day of surgery and 2 days post-surgery.

Control group: follows the usual standard of care. At time moment before surgery and before medication is taken blood and urine sample is taken. This is repeated on day of surgery, and the consecutive 2 days after surgery.

Form these samples biomakers for kidney injury will be measured and compared between groups.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 90 years old (inclusive)
* Undergoing elective cardiac surgery with cardio-pulmonary bypass.
* Providing informed consent

Exclusion Criteria:

Current treatment with SGLT2 inhibitors.

* Diabetes Mellitus Type 1
* BMI\<25 for people with type 2 diabetes
* Reduced renal function at baseline with eGFR \< 30 ml/min.
* Systolic blood pressure \< 100 mmHg at time of inclusion.
* Emergency surgery, defined as in need of surgery for medical reasons \< 7 days, i.e. "S1-4" according to the Amsterdam UMC classification.
* Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods.
* Known or suspected allergy to trial products or other drugs in the same class.
Brain TV (Tissue Velocimetry) for Emergency Assessment of Suspected Stroke

This study uses a Doppler ultrasound technique being developed at the University of Leicester called \&#34;Brain Tissue Velocimetry\&#34; (Brain TV), to investigate brain tissue motion over the cardiac cycle.

Brain motion is highly sensitive to heart and brain biomechanics, but the impact of brain injury on brain tissue motion has yet to be explored. Preliminary brain tissue motion measurements from a small number of patients suggest that brain biomechanics may be disturbed in the presence of brain injury. This study combines transcranial tissue Doppler (TCTD) ultrasound with brain magnetic resonance imaging (MRI) to establish whether analysis of brain tissue motion provides clinically useful information for emergency diagnosis and monitoring of suspected stroke.

Eligibility Criteria:
Inclusion Criteria:

* Participant (or consultee) is willing and able to give informed consent (or assent) for participation in the study.
* Adult, aged 18 years or over.
* Suspected stroke (any severity and any stroke type).

Exclusion Criteria:

* Unable (in the investigators' opinion), or unwilling, to comply with the study requirements.
* Patients with pre-existing chronic brain conditions that may make affect informed consent, such as severe learning difficulties, dementia, or Alzheimer's disease, will be excluded.
A Registered Cohort Study on Spastic Paraplegia

The aim of this study is to determine the clinical spectrum and natural progression of Hereditary Spastic Paraplegias(HSP) and related disorders in a prospective multicenter natural history study, to assess the clinical, genetic and epigenetic features of patients with Spastic Paraplegias to optimize clinicalmanagement..


Eligibility Criteria:
Inclusion Criteria:

* Patients with the clinical diagnosis of spastic paraplegia
* Clinical diagnosis of patients with spastic paraplegia
* Unrelated healthy controls

Exclusion Criteria:

* Decline to participate.
* There are serious interferences with individual participation and adherence to the research protocol, including but not limited to neurological, psychological, and/or medical conditions.
A Multi-Center Trial of Nepicastat for Cocaine Dependence

The objective of this study is to evaluate the safety and efficacy of Nepicastat in improving the number of subjects that achieve abstinence from cocaine and reducing cocaine use in subjects with cocaine dependence.


Eligibility Criteria:
Inclusion Criteria:

* Be at least 18 years of age
* Is seeking treatment for cocaine dependence
* Is able to understand and provide written informed consent
* Has completed all psychological assessments and procedures required during the 7 - 14 day screening period
* If female, agrees to use an acceptable method of birth control
* Is, in the opinion of the Investigator, likely to complete the 11-week Treatment Phase of the study

Exclusion Criteria:

* Please contact the study site for more information
A Study of LY3537021 in Healthy Participants

The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Participants who are overtly healthy as determined through medical evaluation
* Participants with body weight at least 55 kilograms (kg) and body mass index (BMI) of 23.0 to 40.0 kilograms per meter squared (kg/m²)
* Males, or females who are not of childbearing potential.
* Capable of giving signed informed consent form
* Have blood pressure of less than 150/90 millimeters of mercury (mm Hg) and pulse rate of less than 100 beats per minute (bpm) (supine)

Exclusion Criteria:

* Have a significant history of current disorders capable of significantly altering the absorption, metabolism or elimination of drugs
* History of malignancy within 5 years prior to screening
* Have evidence of significant active psychiatric disorder(s)
* Have undergone any form of bariatric surgery
* Have an abnormality in the 12-lead electrocardiogram (ECG)
* Are females who are lactating
Study of the Impact of a Social Telepresence Robot on Social Isolation and Loneliness of the Elderly at Home

The main purpose of this monocentric, prospective study is to measure the impact of the implementation of a robotic social telepresence tool, during three months at home, on the feeling of loneliness and social isolation of the elderly

This non-interventional and prospective study offers elderly people living at home the opportunity to host a social telepresence robot, for a period of three months, with the aim of maintaining a link with those around them and discovering activities offered by professionals (cooking, yoga, visiting virtual museum, etc.) via a networking platform.

This study consists of questionnaires and score calculations, assessing their feeling of loneliness and how they accept the robot in their home.

Subjects will be interviewed one week before the robot arrives at their home, at the start of the study (when the robot arrives).

The follow-up is carried out by a neuropsychologist at 6, 12 and 24 weeks of presence at home.

Data measuring loneliness and social isolation, memory, patient interaction with the robot, their quality of life as well as their emotions will be collected using questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* Subjects aged at least 65 and living at home in Ile-de-France
* Having expressed his non-opposition to his participation in the study
* Agreeing to host a social telepresence robot at home
* Having an internet connection at home

Exclusion Criteria:

* Subject aged under 65 or not living at home in Ile-de-France
* Having expressed his opposition to his participation in the study
* With moderate / major cognitive impairment (Mini-mental state examination (MMSE) \<20)
* Placed under tutorship / curatorship
* Whose housing surface is insufficient for reception and robot movements